Recurrence of non-alcoholic steatohepatitis and cryptogenic cirrhosis following orthotopic liver transplantation in the context of the metabolic syndrome

被引:68
作者
El Atrache, Mazen M. [2 ]
Abouljoud, Marwan S. [1 ]
Divine, George [3 ]
Yoshida, Atsushi [1 ]
Kim, Dean Y. [1 ]
Kazimi, Marwan M. [1 ]
Moonka, Dilip [4 ]
Huang, Mary A. [4 ]
Brown, Kim [4 ]
机构
[1] Henry Ford Hosp, Div Transplant & Hepatobiliary Surg, Detroit, MI 48202 USA
[2] Henry Ford Hosp, Dept Internal Med, Detroit, MI 48202 USA
[3] Henry Ford Hosp, Dept Biostat & Epidemiol, Detroit, MI 48202 USA
[4] Henry Ford Hosp, Dept Gastroenterol & Hepatol, Detroit, MI 48202 USA
关键词
cryptogenic cirrhosis; liver transplantation; metabolic disease; non-alcoholic steatohepatitis; recurrence; INSULIN-RESISTANCE; DISEASE; NASH; ASSOCIATION;
D O I
10.1111/ctr.12014
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background Non-alcoholic steatohepatitis (NASH) and cryptogenic cirrhosis (CC) are increasing indications for orthotopic liver transplantation (OLT). The aim of this study is to describe our outcomes and delineate predictors of recurrence of NASH and CC after OLT. Methods This is a retrospective study from 1996 to 2008. Donor and recipient demographics, metabolic profile, insulin and steroid intake, immunosuppression regimen, operative factors, outcomes, and pathologies were reviewed. Fisher's exact test, Cox regression models, and KaplanMeier plots were used. Results A total of 83 patients were included. Recurrence occurred in 20 patients. Thirty-four percent of the patients with metabolic syndrome (MS) had recurrence of NASH or CC compared with 13% of the patients without MS (p = 0.05). Recurrence also occurred in 32% of the patients with hypertension (HTN) vs. 12% in those without HTN (p = 0.05). Thirty-seven percent of those on insulin had recurrence vs. 6% of those not on insulin (p = 0.05). Five-yr survival probability for patients with MS, HTN, and insulin use was 52%, 61%, and 58%, respectively. Conclusions Higher recurrence of NASH and CC was associated with presence of MS, HTN and insulin use. Recurrence should be further evaluated in larger studies, with special emphasis on management of MS and prevention strategies.
引用
收藏
页码:E505 / E512
页数:8
相关论文
共 29 条
[21]   Cryptogenic cirrhosis and posttransplantation nonalcoholic fatty liver disease [J].
Ong, J ;
Younossi, ZM ;
Reddy, V ;
Price, LL ;
Gramlich, T ;
Mayes, J ;
Boparai, N .
LIVER TRANSPLANTATION, 2001, 7 (09) :797-801
[22]  
Ong JP, 2003, AM J GASTROENTEROL, V98, P1915
[23]   Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: Further evidence for an etiologic association [J].
Pagano, G ;
Pacini, G ;
Musso, G ;
Gambino, R ;
Mecca, F ;
Depetris, N ;
Cassader, M ;
David, E ;
Cavallo-Perin, P ;
Rizzetto, M .
HEPATOLOGY, 2002, 35 (02) :367-372
[24]   Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: A case-control study [J].
Poonawala, A ;
Nair, SP ;
Thuluvath, PJ .
HEPATOLOGY, 2000, 32 (04) :689-692
[25]  
Raoufi M, 2009, LIVER TRANSPLANT, V15, pS266
[26]   Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis. [J].
Sanyal, Arun J. ;
Chalasani, Naga ;
Kowdley, Kris V. ;
McCullough, Arthur ;
Diehl, Anna Mae ;
Bass, Nathan M. ;
Neuschwander-Tetri, Brent A. ;
Lavine, Joel E. ;
Tonascia, James ;
Unalp, Aynur ;
Van Natta, Mark ;
Clark, Jeanne ;
Brunt, Elizabeth M. ;
Kleiner, David E. ;
Hoofnagle, Jay H. ;
Robuck, Patricia R. .
NEW ENGLAND JOURNAL OF MEDICINE, 2010, 362 (18) :1675-1685
[27]  
Seo S, 2007, LIVER TRANSPLANT, V13, P844, DOI 10.1002/lt.20932
[28]   Hyperinsulinemia and insulin resistance in non-alcoholic steatohepatitis [J].
Tankurt, E ;
Biberoglu, S ;
Ellidokuz, E ;
Hekimsoy, Z ;
Akpinar, H ;
Çömlekçi, A ;
Okan, A ;
Sagol, Ö .
JOURNAL OF HEPATOLOGY, 1999, 31 (05) :963-963
[29]   Nonalcoholic Fatty Liver Disease After Liver Transplantation for Cryptogenic Cirrhosis or Nonalcoholic Fatty Liver Disease [J].
Yalamanchili, Kanthi ;
Saadeh, Sherif ;
Klintmalm, Goeran B. ;
Jennings, Linda W. ;
Davis, Gary L. .
LIVER TRANSPLANTATION, 2010, 16 (04) :431-439